N6-methyladenosine-modified SRD5A3, identified by IGF2BP3, sustains cisplatin resistance in bladder cancer
2025

How SRD5A3 and IGF2BP3 Affect Bladder Cancer and Chemotherapy Resistance

Sample size: 30 publication 10 minutes Evidence: high

Author Information

Author(s): Liao Kai, Li Jing, He Caixian, Peng Jiyong

Primary Institution: Guangzhou Institute of Cancer Research, The Affiliated Cancer Hospital, Guangzhou Medical University

Hypothesis

The study investigates the role of SRD5A3 and IGF2BP3 in bladder cancer and their impact on cisplatin resistance.

Conclusion

The study found that SRD5A3 and IGF2BP3 contribute to bladder cancer progression and cisplatin resistance, suggesting potential therapeutic targets.

Supporting Evidence

  • SRD5A3 was found to be upregulated in cisplatin-resistant bladder cancer cells.
  • Knockdown of SRD5A3 and IGF2BP3 reduced cell proliferation and chemoresistance.
  • Animal studies showed that SRD5A3 knockdown inhibited tumor growth in xenografts.

Takeaway

This study shows that two proteins, SRD5A3 and IGF2BP3, help bladder cancer cells survive chemotherapy, which means targeting them could help treat the cancer better.

Methodology

The study used human bladder cancer tissues, cell lines, and animal models to analyze the roles of SRD5A3 and IGF2BP3 in cisplatin resistance.

Limitations

The exact mechanisms by which SRD5A3 contributes to cisplatin resistance remain unclear.

Participant Demographics

Among the 30 bladder cancer patients, there were 21 males and 9 females, with varying stages of cancer.

Statistical Information

P-Value

p<0.0001

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1007/s13577-024-01136-0

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication